Forte Biosciences (NASDAQ:FBRX – Get Free Report) and Aytu BioPharma (NASDAQ:AYTU – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Analyst Ratings
This is a summary of current ratings and target prices for Forte Biosciences and Aytu BioPharma, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Forte Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Aytu BioPharma | 0 | 0 | 0 | 0 | 0.00 |
Forte Biosciences presently has a consensus target price of $23.58, suggesting a potential upside of 32.64%. Given Forte Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Forte Biosciences is more favorable than Aytu BioPharma.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Forte Biosciences | N/A | N/A | -$31.48 million | ($16.29) | -1.09 |
Aytu BioPharma | $79.76 million | 0.13 | -$15.84 million | ($1.23) | -1.41 |
Aytu BioPharma has higher revenue and earnings than Forte Biosciences. Aytu BioPharma is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Forte Biosciences and Aytu BioPharma’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Forte Biosciences | N/A | -151.43% | -118.92% |
Aytu BioPharma | -8.28% | -21.89% | -5.37% |
Volatility and Risk
Forte Biosciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.43, suggesting that its stock price is 243% less volatile than the S&P 500.
Insider & Institutional Ownership
77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 3.1% of Forte Biosciences shares are held by insiders. Comparatively, 2.8% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Forte Biosciences beats Aytu BioPharma on 8 of the 13 factors compared between the two stocks.
About Forte Biosciences
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
About Aytu BioPharma
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine – for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.